Meridian Introduces Critical Raw Materials for Nipah Virus Diagnosis, a Key Emerging Disease on the WHO’s Priority List
May 30, 2018 10:54 ET
|
Meridian Bioscience Inc.
CINCINNATI, May 30, 2018 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the availability of critical antigens and antibodies for Nipah virus immunological assay...
Meridian Bioscience Reports Second Quarter 2018 Operating Results, Declares Regular Second Quarter Cash Dividend, and Updates Fiscal 2018 Guidance
April 26, 2018 07:30 ET
|
Meridian Bioscience Inc.
CINCINNATI, April 26, 2018 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today: GENERAL HIGHLIGHTS Reported record fiscal 2018 second quarter and first six months net revenues of...
Meridian Bioscience, Inc. Expects to Report Second Quarter Fiscal Year 2018 Operating Results on Thursday, April 26, 2018
April 04, 2018 10:00 ET
|
Meridian Bioscience Inc.
CINCINNATI, April 04, 2018 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading diagnostic and life science component company, expects to release its second quarter fiscal 2018...
Meridian Bioscience Realigns Organizational Structure
March 21, 2018 07:30 ET
|
Meridian Bioscience Inc.
New Structure Consists of two Business Units, Diagnostics and Life Science, Supported by a Global Corporate Team Realignment Aimed at Building a Stronger, More Sustainable Organization; Paving the...
Meridian Bioscience Reports First Quarter 2018 Operating Results, Declares Regular First Quarter Cash Dividend, and Reaffirms Fiscal 2018 Guidance
January 25, 2018 07:15 ET
|
Meridian Bioscience Inc.
CINCINNATI, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today: GENERAL HIGHLIGHTS reported first quarter net revenues of $52.3 million, an increase of 12% from the...
Meridian Bioscience, Inc. Expects to Report First Quarter Fiscal Year 2018 Operating Results on Thursday, January 25, 2018
January 19, 2018 16:23 ET
|
Meridian Bioscience Inc.
CINCINNATI, Jan. 19, 2018 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading diagnostic and life science component company, expects to release its first quarter fiscal 2018...
Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Declares Regular Fourth Quarter Cash Dividend, Sets Fiscal 2018 Cash Dividend Rate, and Reaffirms Fiscal 2018 Guidance
November 09, 2017 07:30 ET
|
Meridian Bioscience Inc.
GENERAL HIGHLIGHTS CINCINNATI, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today: reported fourth quarter and full-year fiscal 2017 net revenues of $49.7 million and...
Meridian Bioscience Comments on FDA Press Statement Regarding Its Warning Letter Issued to Magellan Diagnostics
October 23, 2017 17:30 ET
|
Meridian Bioscience Inc.
CINCINNATI, Oct. 23, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that the FDA has issued a Warning Letter related to matters at its Magellan Diagnostics...
Meridian Bioscience, Inc. Comments on Preliminary Fiscal 2017 Operating Results and Provides Fiscal 2018 Revenue and Earnings Guidance
October 19, 2017 07:30 ET
|
Meridian Bioscience Inc.
CINCINNATI, Oct. 19, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that based on preliminary results, it expects revenues for fiscal 2017, ended on September 30,...
Meridian Bioscience, Inc. Expects to Report Fiscal 2018 Revenue and Earnings Guidance on Thursday, October 19, 2017
October 16, 2017 16:30 ET
|
Meridian Bioscience Inc.
CINCINNATI, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading diagnostic and life science component company, expects to release its fiscal 2018 Revenue and...